Blog
May 15, 2023
Poster sessions at AACR: a recap
We were grateful for the opportunity to attend and present at the AACR Annual Meeting last week, where three of our scientists highlighted some of the exciting work happening in our Vancouver lab.
Personalized cancer treatment via targeted therapies is two-to-three times more effective than standard chemotherapy for patients with advanced or metastatic cancer. But for patients to benefit, they must have access to robust biomarker testing capabilities, a challenge in many community cancer settings. Yet this testing is time-consuming and costly to outsource.
The solution? Canexia Health can help your lab deploy cancer genomics assays at a fraction of the cost of outsourcing multigene panels to a centralized lab, and without the need to invest in a costly bioinformatics infrastructure.
Our Clinical Services team supports labs with bringing precision oncology programs in-house, including the implementation and maintenance of clinical next-generation sequencing-based profiling.
Watch our video to learn how we can help you deliver on your mandate for providing best-in-class cancer care.
Recent Resources
Press
March 28, 2023
Imagia Canexia Health Announces Three Abstracts to be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Latest Research Findings
Imagia Canexia Health announced that three abstracts highlighting the company’s new learnings and tools will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.
Webinar
March 27, 2023
Project ACTT Webinar
Project ACTT (Access to Cancer Testing and Treatment) in Response to COVID-19 was a joint effort led by Imagia Canexia Health and supported by Digital Supercluster and partner institutions.